Clinical development success rates for investigational drugs

Keywords

Investigational Drugs, Drug development, Drug approval, Medicine, Intensive care medicine

References

• 2012 FDA drug approvals清司 上月, 毅 相本, 武己 矢崎 — 2013
• Macro trends in pharmaceutical innovationFredric J. Cohen — 2005
• Can the pharmaceutical industry reduce attrition rates?Ismail Kola, J. Richard Landis — 2004
• Success rates in the United States drug development systemLorraine E. Sheck, Christopher Cox, Henry T. Davis — 1984
• The cost of biopharmaceutical R&D: is biotech different?Joseph A. DiMasi, Henry G. Grabowski — 2007
• Risks in new drug development: Approval success rates for investigational drugsJoseph A. DiMasi — 2001
• Success rates for new drugs entering clinical testing in the United StatesJoseph A. DiMasi — 1995
• Trends in Risks Associated With New Drug Development: Success Rates for Investigational DrugsJoseph A. DiMasi, Laurent J. Feldman, A Seckler — 2010
• Pharmaceutical Development Phases: A Duration AnalysisRosa M. Abrantes-Metz, Christopher Adams, Albert Metz — 2006
• Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009K I Kaitin, JA DiMasi — 2011
• The price of innovation: new estimates of drug development costs.Joseph A. DiMasi, Ronald W. Hansen, Henry G. Grabowski — 2003
• A Breath of Fresh Air? Firm Type, Scale, Scope, and Selection Effects in Drug DevelopmentAshish Arora, Alfonso Gambardella, Laura Magazzini — 2009
• Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances.Patricia M. Danzon, Sean Nicholson, Nuno Sousa Pereira — 2003
• Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research.Iain Cockburn, Rebecca Henderson — 2001
• Proceedings of the American Society of Clinical OncologyJ. Korinek, A. Bedikian, J. Stroehlein — 1982

Cited by

• Companion animals: Translational scientist’s new best friendsLuiz Carlos Severo — 2015
• The great debate: Should Osteoarthritis Research Focus on "Mice" or "Men"?Cristiana Pena — 2016
• Comparative aspects of rodent and nonrodent animal models for mechanistic and translational diabetes research.María Paz García Rubio — 2016
• A recapitulative three-dimensional model of breast carcinoma requires perfusion for multi-week growthKayla F. Goliwas, Lauren E. Marshall, Evette L Ransaw — 2016
• Neurotrophin receptor agonists and antagonists as therapeutic agents: An evolving paradigm.Robert S. Erikson — 2017
• A complex game of hide and seek: the search for new antifungals純 森泉, 康一郎 永峰, 孝夫 飯田 — 2016
• Scalpels not hammers: The way forward for precision drug prescriptionJoanna Ptasińska — 2017
• In Vivo Imaging in Pharmaceutical Development and Its Impact on the 3RsHong Xu — 2016
• New approaches to antibiotic discoveryMarcos Oliveira de Carvalho — 2017
• Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer.Троцковский Александр Яковлевич, Мищенко Инна Витальевна — 2017
• Re-inventing drug development: A case study of the I-SPY 2 breast cancer clinical trials program.Lahsen Bougdal — 2017
• Human Cortex Spheroid with a Functional Blood Brain Barrier for High-Throughput Neurotoxicity Screening and Disease ModelingAntonio Ojeda Guerra, Rodrigo Martín Hernández — 2018
• PathwayMap: Molecular Pathway Association with Self-Normalizing Neural NetworksHelena Suárez de la Dehesa — 2018
• Potential Anti-Cancer Flavonoids Isolated From Caesalpinia bonduc Young Twigs and Leaves: Molecular Docking and In Silico StudiesKaren N. DSouza, Rod Whyte, Leanne Basham — 2019
• Prioritization of cancer therapeutic targets using CRISPR–Cas9 screensMaría del Carmen Barrigón Fuentes — 2019
• Algorithmic benchmark modulation: A novel method to develop success rates for clinical studiesP. Chaumette — 2023
• Animal paradigms to assess cognition with translation to humans.Tanya L. Wallace, Theresa M. Ballard, Courtney Glavis‐Bloom — 2015
• Status and Prospects of Aptamers as Drug ComponentsChristopher Mattice, Maria C. DeRosa — 2015
• The business impact of an integrated continuous biomanufacturing platform for recombinant protein production.Jason Walther, Rahul Godawat, Chris Hwang — 2015
• Pioneering better science through the 3Rs: an introduction to the national centre for the replacement, refinement, and reduction of animals in research (NC3Rs).Natalie Burden, Kathryn Chapman, Fiona Sewell — 2015

Related papers

• Exploratory Investigational New Drug (IND) Studies in HumansVijay Tammara, David Jacobson‐Kram — 2007
• A comparison of FDA and EMA drug approval: implications for drug development and cost of care.Lynn Howie, Bradford R. Hirsch, Amy P. Abernethy — 2013
• A guide to drug discovery: Trends in development and approval times for new therapeutics in the United StatesJanice M. Reichert — 2003
• １．早期探索的臨床試験と「承認」に向けた開発戦略： 趣旨説明と今後の展望栗原 千絵子 — 2012
• Regulatory watch: FDA guidance on co-developing investigational drugs2011
• Risks in new drug development: Approval success rates for investigational drugsJoseph A. DiMasi — 2001
• Drugs in clinical development for the treatment of amyotrophic lateral sclerosisAna Martı́nez, Maria del Valle Palomo Ruiz, Daniel I. Pérez — 2017
• Call Made to Speed Cell-Therapy Development.2019